Beyond breast carcinomas: the attenuating effect on tumor growth in other systemic malignancies by raloxifene
This study investigates the potential use of raloxifene, a selective estrogen receptor modulator (SERM), in treating cancers beyond breast carcinoma. The research highlights raloxifene’s effects on tumor growth in various systemic malignancies, including endometrial, ovarian, and prostate cancers. The study concludes that raloxifene may provide a therapeutic benefit by inhibiting
June 26, 2025
No Comments